Avalo Therapeutics, Inc. (AVTX)
7.30
-0.02
(-0.27%)
USD |
NASDAQ |
Nov 03, 11:43
Avalo Therapeutics Price to Book Value : 0.8607 for Nov. 3, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 02, 2026 | 0.8631 |
| October 30, 2026 | 0.8454 |
| October 29, 2026 | 0.8772 |
| October 28, 2026 | 0.8395 |
| October 27, 2026 | 0.7959 |
| October 26, 2026 | 0.7982 |
| October 23, 2026 | 0.8171 |
| October 22, 2026 | 0.8784 |
| October 21, 2026 | 1.446 |
| October 20, 2026 | 1.457 |
| October 19, 2026 | 1.367 |
| October 16, 2026 | 1.329 |
| October 15, 2026 | 1.416 |
| October 14, 2026 | 1.396 |
| October 13, 2026 | 1.416 |
| October 12, 2026 | 1.561 |
| October 09, 2026 | 1.609 |
| October 08, 2026 | 1.584 |
| October 07, 2026 | 1.601 |
| October 06, 2026 | 1.602 |
| October 05, 2026 | 1.722 |
| October 02, 2026 | 1.767 |
| October 01, 2026 | 1.763 |
| September 30, 2026 | 1.808 |
| September 29, 2026 | 1.837 |
| Date | Value |
|---|---|
| September 28, 2026 | 1.778 |
| September 25, 2026 | 1.824 |
| September 24, 2026 | 1.854 |
| September 23, 2026 | 1.804 |
| September 22, 2026 | 1.947 |
| September 21, 2026 | 1.907 |
| September 18, 2026 | 1.954 |
| September 17, 2026 | 1.968 |
| September 16, 2026 | 1.955 |
| September 15, 2026 | 1.895 |
| September 14, 2026 | 1.908 |
| September 11, 2026 | 1.901 |
| September 10, 2026 | 2.026 |
| September 09, 2026 | 2.147 |
| September 08, 2026 | 2.324 |
| September 04, 2026 | 2.267 |
| September 03, 2026 | 2.240 |
| September 02, 2026 | 2.280 |
| September 01, 2026 | 2.234 |
| August 31, 2026 | 2.280 |
| August 28, 2026 | 2.310 |
| August 27, 2026 | 2.364 |
| August 26, 2026 | 2.423 |
| August 25, 2026 | 2.328 |
| August 24, 2026 | 2.272 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| AbbVie, Inc. | -- |
| ACADIA Pharmaceuticals, Inc. | 2.735 |
| Alnylam Pharmaceuticals, Inc. | 5.927 |
| Anika Therapeutics, Inc. | 1.879 |
| Savara, Inc. | 6.806 |
Price to Book Value Related Metrics
| PS Ratio | 2976.36 |
| Price | 7.30 |
| Earnings Yield | -64.91% |
| Market Cap | 386.18M |